Evidence map›Paper›PMID 38189759›Full record

ArticleJournal of neuromuscular diseases2024

Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study.

Giulia Ricci, Alessandra Govoni, Francesca Torri, Guja Astrea, Bianca Buchignani, Gemma Marinella, Roberta Battini, Maria Laura Manca, Vincenzo Castiglione, Alberto Giannoni and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of neuromuscular diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Giulia RicciDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Alessandra GovoniNeuromuscular and Rare Disease Unit, La Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, Milano, Italy.
Francesca TorriDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Guja AstreaDepartment of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
Bianca BuchignaniDepartment of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
Gemma MarinellaDepartment of Developmental Neuroscience, IRCCS Stella Maris, Calambrone, Pisa, Italy.
Roberta BattiniDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Maria Laura MancaDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Vincenzo CastiglioneHealth Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
Alberto GiannoniHealth Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
Michele EmdinHealth Science Interdisciplinary Center, Scuola Superiore Sant'Anna, Pisa, Italy.
Gabriele SicilianoDepartment of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
University of Pisa · ITScuola Superiore Sant'Anna · ITFondazione Stella Maris · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Becker muscular dystrophy (BMD) is a dystrophinopathy due to in-frame mutations in the dystrophin gene (DMD) which determines a reduction of dystrophin at muscle level. BMD has a wide spectrum of clinical variability with different degrees of disability. Studies of natural history are needed also in view of up-coming clinical trials. Objectives: From an initial cohort of 32 BMD adult subjects, we present a detailed phenotypic characterization of 28 patients, then providing a description of their clinical natural history over the course of 12 months for 18 and 24 months for 13 of them. Methods: Each patient has been genetically characterized. Baseline, and 1-year and 2 years assessments included North Star Ambulatory Assessment (NSAA), timed function tests (time to climb and descend four stairs), 6-minute walk test (6MWT), Walton and Gardner-Medwin Scale and Medical Research Council (MRC) scale. Muscle magnetic resonance imaging (MRI) was acquired at baseline and in a subgroup of 9 patients after 24 months. Data on cardiac function (electrocardiogram, echocardiogram, and cardiac MRI) were also collected. Results and conclusions: Among the clinical heterogeneity, a more severe involvement is often observed in patients with 45-X del, with a disease progression over two years. The 6MWT appears sensitive to detect modification from baseline during follow up while no variation was observed by MRC testing. Muscle MRI of the lower limbs correlates with clinical parameters.Our study further highlights how the phenotypic variability of BMD adult patients makes it difficult to describe an uniform course and substantiates the need to identify predictive parameters and biomarkers to stratify patients.

Indexed as

Muscular Dystrophy, DuchenneAdultBiological Variation, PopulationDystrophinFollow-Up StudiesHumansMuscle, SkeletalDystrophin

Identifiers

PMID38189759
PMCPMC10977409
OpenAlexW4390619017

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.